Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylnaltrexone extension in advanced illness with OIC
NCT00672139Phase 4Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Jul 2008
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 4, open-label, single-arm trial of methylnaltrexone in opioid-induced constipation (OIC), sponsored by Valeant Pharmaceuticals. Primary endpoint: Number of Laxations Per Subject Within 24 Hours of Dosing Per Week. Started Jul 2008; status: completed.
02
Drugs
methylnaltrexone
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on NCT00672139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00672139.